Exelixis' Cometriq Makes a Comeback
Exelixis reports third quarter earnings, but it's the data testing Cometriq in lung cancer that's caused the stock pop.
Why Exelixis, Inc. Stock Pushed 11% Higher in October
Exelixis was one of the best biotech stocks in October. Find out what sent its shares higher by 11% and whether or not the good times will keep rolling for this small-cap biotech stock.
Is Exelixis, Inc. Stock a Bad News Buy?
Is the 75% drop in Exelixis, Inc. stock justified? Two of our top analysts weigh in and discuss the company's potential as a "bad news buy".